Výsledky vyhledávání - "Philip M. MacLaughlin"

Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans. Part A: Use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities

Autor: Naomi L. Kruhlak, Edwin J. Matthews, Joseph F. Contrera, Carling Ursem, Philip M. MacLaughlin, R. Daniel Benz

Publikováno v: Regulatory Toxicology and Pharmacology. 54:1-22

The Informatics and Computational Safety Analysis Staff at the US FDA’s Center for Drug Evaluation and Research has created a database of pharmaceutical adverse effects (AEs) linked to pharmaceutical chemical structures and estimated population exp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb5d56a3f990770a8abc2481a5ae0508
https://doi.org/10.1016/j.yrtph.2008.12.009

Zobrazit plný text záznamu

QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors

Autor: Joseph F. Contrera, Lowell H. Hall, Lemont B. Kier, Philip M. MacLaughlin

Publikováno v: Current drug discovery technologies. 2(2)

A discriminant analysis model is presented for carcinogenic risk. The data set is obtained from the two-year rodent study FDA/CDER database and was divided into a training set of 1022 organic compounds and an external validation test set of 50 compou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089195b5c85a9a0a47b662c3536a1f19
https://pubmed.ncbi.nlm.nih.gov/16472230

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání